Immunomedics announces U.S. patent for IMMU-144 Immunomedics announced the issuance of U.S. patent no. 8,722,047 for the company's patent application "Humanized anti-HLA-DR antibodies," with an expiration date of May 26, 2026. The new patent concerns compositions of humanized anti-HLA-DR antibodies of use for disease therapy. The allowed claims protect IMMU-114, which is being investigated as a monotherapy in a newly-opened Phase I dose-escalation trial in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.
News For IMMU From The Last 14 Days
Check below for free stories on IMMU the last two weeks.